Predictors of unstable anticoagulation in African Americans

Journal of Thrombosis and Thrombolysis

Volumn 27, Issue 4, 2009, Pages 430-437

  Cavallari, Larisa H ^a   Aston, Jonathan L ^a   Momary, Kathryn M ^a   Shapiro, Nancy L ^a   Patel, Shitalben R ^a   Nutescu, Edith A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

African American; Genotype; International normalized ratio; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

ADULT; AFRICAN AMERICAN; AGE; ANTICOAGULANT THERAPY; ARTICLE; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; LONG TERM CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RACE DIFFERENCE; SMOKING; VOMITING;

AFRICAN AMERICANS; AGED; ANTICOAGULANTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PATIENT COMPLIANCE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; VOMITING; WARFARIN;

EID: 67349088363     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-008-0236-8     Document Type: Article

References (28)

1. White HD, Gruber M, Feyzi J et al (2007) Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: Results from SPORTIF III and V. Arch Intern Med 167(3):239-245. doi: 10.1001/archinte.167.3.239
2. Chiquette E, Amato MG, Bussey HI (1998) Comparison of an anticoagulation clinic with usual medical care: Anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 158(15):1641-1647. doi: 10.1001/archinte.158.15.1641
3. Abdelhafiz AH, Wheeldon NM (2003) Use of resources and cost implications of stroke prophylaxis with warfarin for patients with nonvalvular atrial fibrillation. Am J Geriatr Pharmacother 1(2):53-60. doi: 10.1016/ S1543-5946(03)90001-8
4. Holbrook AM, Pereira JA, Labiris R et al (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165(10):1095-1106. doi: 10.1001/archinte.165.10.1095
5. Lubetsky A, Dekel-Stern E, Chetrit A, Lubin F, Halkin H (1999) Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thromb Haemost 81(3):396-399
6. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL (2004) Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 91(1):87-94
7. Rieder MJ, Reiner AP, Gage BF et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352(22):2285-2293. doi: 10.1056/NEJMoa044503
8. Margaglione M, Colaizzo D, D'Andrea G et al (2000) Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 84(5):775-778
9. Marsh S, King CR, Porche-Sorbet RM, Scott-Horton TJ, Eby CS (2006) Population variation in VKORC1 haplotype structure. J Thromb Haemost 4(2):473-474. doi: 10.1111/j.1538-7836.2006.01759.x
10. Takahashi H, Wilkinson GR, Nutescu EA et al (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 16(2):101-110
11. Andrisin TE, Humma LM, Johnson JA (2002) Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies. Pharmacotherapy 22(8):954-960. doi: 10.1592/phco.22.12.954.33598
12. Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH (2007) Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics 8(11):1535-1544. doi: 10.2217/ 14622416.8.11.1535
13. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E (2004) The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl):204-233. doi: 10.1378/chest.126.3_suppl.204 S
14. Hruska MW, Frye RF, Langaee TY (2004) Pyrosequencing method for genotyping cytochrome P450 CYP2C8 and CYP2C9 enzymes. Clin Chem 50(12):2392-2395. doi: 10.1373/clinchem.2004.040071
15. Aquilante CL, Langaee TY, Lopez LM et al (2006) Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 79(4):291-302. doi: 10.1016/j.clpt.2005.11.011
16. Wittkowsky AK, Devine EB (2004) Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy 24(10):1311-1316. doi: 10.1592/ phco.24.14.1311.43144
17. Hylek EM, Go AS, Chang Y et al (2003) Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349(11):1019-1026. doi: 10.1056/NEJMoa022913
18. Hylek EM, Singer DE (1994) Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 120(11):897-902
19. Palareti G, Legnani C, Guazzaloca G et al (2005) Risks factors for highly unstable response to oral anticoagulation: A case-control study. Br J Haematol 129(1):72-78. doi: 10.1111/j.1365-2141.2005.05417.x
20. Laporte S, Quenet S, Buchmuller-Cordier A et al (2003) Compliance and stability of INR of two oral anticoagulants with different half-lives: A randomised trial. Thromb Haemost 89(3):458-467
21. Waterman AD, Milligan PE, Bayer L, Banet GA, Gatchel SK, Gage BF (2004) Effect of warfarin nonadherence on control of the International Normalized Ratio. Am J Health Syst Pharm 61(12):1258-1264
22. Schalekamp T, Brasse BP, Roijers JF et al (2007) VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: Interaction between both genotypes affects dose requirement. Clin Pharmacol Ther 81(2):185-193. doi: 10.1038/sj.clpt.6100036
23. Anderson JL, Horne BD, Stevens SM et al (2007) Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22):2563-2570. doi: 10.1161/ CIRCULATIONAHA.107.737312
24. Higashi MK, Veenstra DL, Kondo LM et al (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13):1690-1698. doi: 10.1001/jama.287.13.1690
25. Sconce E, Avery P, Wynne H, Kamali F (2007) Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 109(6):2419-2423. doi: 10.1182/blood-2006-09-049262
26. Sawicki PT (1999) A structured teaching and self-management program for patients receiving oral anticoagulation a randomized controlled trial working group for the study of patient self-management of oral anticoagulation. JAMA 281(2):145-150. doi: 10.1001/jama.281.2.145
27. Lee JK, Grace KA, Taylor AJ (2006) Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: A randomized controlled trial. JAMA 296(21):2563-2571. doi: 10.1001/jama.296.21.joc60162
28. Schmitt L, Speckman J, Ansell J (2003) Quality assessment of anticoagulation dose management: Comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis 15(3):213-216. doi: 10.1023/B:THRO.0000011377.78585.63